TMCnet News
Research and Markets: Global Migraine Drug Forecast and Market Analysis to 2023 - A Potential $3.7 Billion MarketDUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/vhfw9w/pharmapoint) has announced the addition of the "PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023" report to their offering. The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine populaton. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile. Key Findings
Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned
For more information visit http://www.researchandmarkets.com/research/vhfw9w/pharmapoint
|